Table 1: Baseline characteristics of patients included in
the meta-analysis.
|
Study |
Country |
Treatment
regimen |
No.
of patients |
♀ Female/
♂ Male |
Age
(Mean, SD) |
BMI1 (Mean,
SD) |
Vitamin D3 (ng/ml) (Mean, SD) |
|
Sanghi 2013 |
India |
60.000 IU daily vitamin D3, Placebo. |
N=103 VD3=52 PL4=51
|
66♀ and 37♂ VD (30♀/21♂) PL (36♀/16♂) |
VD2: 53.24 (9.64) PL3: 53.00 (7.44) |
VD: 25.86 (2.46) PL: 25.65 (2.58) |
VD: 14.812
(3.012) PL: 15.008 (3.012) |
|
McAlindon
2013 |
USA |
2.000 IU daily vitamin
D3, Placebo. |
N=146 VD=73 PL=73
|
89♀
and 57♂ VD (49♀/24♂) PL (40♀/33♂) |
VD:
61.8 (7.7) PL:
63.0 (9.3) |
VD:
30.5 (5.0) PL:
30.8 (6.4) |
VD:
22.7 (11.4) PL:
21.9 (1.7) |
|
Jin 2016 |
Australia |
50.000 IU daily vitamin D3, Placebo. |
N=413 VD=209 PL=204
|
208♀ and 205♂ VD (106♀/103♂) PL (102♀/102♂) |
VD: 63.5 (6.9) PL: 62.9 (7.2) |
VD: 29.6 (5.4) PL: 29.6 (4.6) |
VD: 17.48 (4.72) PL: 17.52 (5.08) |
|
Arden
2016 |
UK |
800 IU daily vitamin D3, Placebo. |
N=474 VD=237 PL=
237
|
289♀
and 185♂ VD (144♀/93♂) PL (145♀/92♂) |
VD:
64 (8) PL:
64 (8) |
VD:
30 (5) PL:
29 (5) |
VD:
20.7 (8.9) PL:
20.7 (8.1) |
|
Zheng 2017 |
Australia |
50.000 IU daily
vitamin D3, Placebo. |
N=340 CI=46 FL=68 CS=226
|
160♀ and 180♂ CI (24♀ and 22♂) FL (38♀/30♂) CS (98♀/128♂) |
CI4:62.6 (8.0) F5: 62.9 (6.1) CS6: 63.5 (7.2) |
CI: 30.6 (4.6) F: 29.0 (4.5) CS: 29.4 (4.9) |
CI: ≤ 20 ng/ml F: > 20 ng/ml at either point CS: > 20 ng/ml at both months 3 and
24. |
|
Wang
2017 |
Australia |
50.000 IU daily vitamin D3, Placebo. |
N=413 VD=209 PL=204
|
208♀
and 205♂ VD (106♀/103♂) PL (102♀/102♂) |
VD:
63.55 (6.88) PL:
62.55 (7.22) |
VD:
29.57 (5.39) PL:
29.64 (4.62) |
VD:
17.496 (4.72) PL:
17.524 (5.06) |
|
Zheng 2018 |
Australia |
50.000 IU daily
vitamin D3, Placebo. |
N=200 VD=106 PL=94
|
107♀ and 93♂ VD (53♀/53♂) PL (54♀/40♂) |
VD: 63.3 (7.5) PL: 62.8 (7.3) |
VD: 29.4 (7.5) PL: 29.6 (4.0) |
VD: 17 (4.68) PL: 17.4 (5.04) |
|
Barker
2019 |
USA |
4.000 IU daily vitamin D3, Placebo. |
N=29 VD=14 PL=15 |
16♀
and 13♂ VD (8♀/7♂) PL (8♀/6♂) |
VD:
51.1 (1.16) PL:
46.8 (2.7) |
VD:
32.9 (1.7) PL:
31.6 (1.4) |
VD:
27.5 (1.5) PL:
27.5 (1.5) |
|
Perry 2019
|
UK |
800 IU daily vitamin D3, Placebo. |
N=50 VD=24 PL=26 |
37♀ and 13♂ VD (17♀/7♂) PL (20♀/6♂) |
VD: 63.0 (5.8) PL: 63.6 (7.2) |
VD: 28.2 (4.0) PL: 29.2 (5.6) |
VD: 26.6 (8.5) PL: 25.3 (8.7) |
1BMI:
Body Mass Index; 2VD: Vitamin D group; 3PL: Placebo
group; 4CI: Consistently Insufficient; 5F: Fluctuating; 6CS:
Consistently Sufficient.